We'll see... they've still got to get past the FDA. But thank you for bringing up another potential competitor coming down the pike!

The biggest holdup so far has been the FDA. The FDA previously issued a CRL for Teva's submission, asking for additional information from the companies in order to be able to approve the ANDA. Investors in Antares are beholden to how quickly Teva will be able to resubmit the application. After the receipt of the CRL, Teva admitted that there were certain 'major deficiencies' in the application. This puts the timeline for approval into 2017. The timeline could be even later if there is any delay in fulfilling the FDA's requirements. Teva will need to move forward as quickly as possible in order to get its generic EpiPen approved.

Link: Antares Pharmaceuticals: The Stock To Buy On EpiPen Issues